Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study

Study limitation reported by the research below: “This is a single-arm phase 2 study; absence of a randomized comparator limits causal inference for biomarker-outcome associations.”